HomeTagsPrecigen

Precigen

Biotechnology

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T

Renuka Gurav - April 4, 2023

Precigen, Inc, a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced the amendment...

Biotechnology

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

PR Newswire - August 24, 2022

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the...

Biotechnology

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

PR Newswire - July 6, 2022

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the...

Interos Appoints Tech Visionaries Yardley Pohl and Chris Lee to Executive…

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Ansys Joins Intel Foundry’s United States Military, Aerospace, and Government (USMAG)…

proteanTecs Launches Advanced Real-Time Safety Monitoring (RTSM™) for Automotive Electronics

Precigen

Hot Topics

Interos Appoints Tech Visionaries Yardley Pohl and Chris Lee to Executive Management Team

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Ansys Joins Intel Foundry’s United States Military, Aerospace, and Government (USMAG) Alliance